LUCID is collaborating with JT, a Japanese pharma company, to apply their clinical data for the development of music therapy for patients suffering from dementia, specifically Alzheimer’s. LUCID executed a randomised controlled clinical trial earlier this year that demonstrated a decrease in acute and moderate anxiety amongst adults. Alzheimer’s is coupled with anxiety, aggression, and other neuropsychiatric symptoms, which not only are a nuisance for the patients, but also lead to burnout of caregivers. With JT’s funding, LUCID aims to provide an inexpensive personalised music therapy service by employing AI and technology, and other cloud-based applications.
Read More from BusinessWire
